ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Autor: Duygu Tosun, Jozef Hanes, Branislav Kovacech, Tomas Hromadka, Lutz Froelich, Stanislav Katina, Lubica Fialova, Michal Prcina, Norbert Zilka, Andrej Kovac, Reinhold Schmidt, Eva Kontsekova, Martin Rakusa, Martin Cente, Carmen Prenn-Gologranc, Milica G. Kramberger, Stanislav Sutovsky, Peter Koson, Markus Otto, Stefan Ropele, Petr Novak, John Harrison, Michal Novak, Roman Sivak, Juraj Piestansky, Matej Ondrus, Jaroslav Galba, Miroslav Smisek, Maria Samcova, Eva Stevens, Jakub Hort, Bengt Winblad, Philip Scheltens, Vojtech Parrak, Peter Filipcik, Michal Fresser, Natalia Paulenka-Ivanovova

Publikováno v: Nature Aging, 1(6), 521-534. Springer
Novak, P, Kovacech, B, Katina, S, Schmidt, R, Scheltens, P, Kontsekova, E, Ropele, S, Fialova, L, Kramberger, M, Paulenka-Ivanovova, N, Smisek, M, Hanes, J, Stevens, E, Kovac, A, Sutovsky, S, Parrak, V, Koson, P, Prcina, M, Galba, J, Cente, M, Hromadka, T, Filipcik, P, Piestansky, J, Samcova, M, Prenn-Gologranc, C, Sivak, R, Froelich, L, Fresser, M, Rakusa, M, Harrison, J, Hort, J, Otto, M, Tosun, D, Ondrus, M, Winblad, B, Novak, M & Zilka, N 2021, ' ADAMANT : a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease ', Nature Aging, vol. 1, no. 6, pp. 521-534 . https://doi.org/10.1038/s43587-021-00070-2

Alzheimer’s disease (AD) pathology is partly characterized by accumulation of aberrant forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel-arm, randomized phase 2 multicenter placebo-controlled trial of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9207a075a751b59f0b0c380b710aaf1
https://research.vumc.nl/en/publications/61abe2cc-82ad-4ac3-93be-d1cbc548881b

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Autor: Norbert Zilka, Peter Dal-Bianco, Branislav Kovacech, Roman Sivak, Michal Prcina, Stefan Ropele, Lubica Fialova, Eva Kontsekova, Vojtech Parrak, Michael Rainer, Bengt Winblad, Miroslav Smisek, Michal Novak, Martin Brunner, Tomas Smolek, Reinhold Schmidt, Petr Novak, Matej Ondrus, Stanislav Katina, Wolfgang Staffen

Publikováno v: Alzheimer's Research & Therapy
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-16 (2018)

Background Neurofibrillary pathology composed of tau protein is closely correlated with severity and phenotype of cognitive impairment in patients with Alzheimer’s disease and non-Alzheimer’s tauopathies. Targeting pathological tau proteins via i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f9841552af8204d4d0b90bb0752c732
http://europepmc.org/articles/PMC6201586